Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) is expected to post its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect the company to announce earnings of ($0.28) per share for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 3:00 PM ET.
Brainstorm Cell Therapeutics Price Performance
Brainstorm Cell Therapeutics stock opened at $0.90 on Friday. The stock has a market capitalization of $9.91 million, a PE ratio of -0.27 and a beta of 0.69. The business has a 50 day simple moving average of $0.67 and a 200-day simple moving average of $0.65. Brainstorm Cell Therapeutics has a 12 month low of $0.46 and a 12 month high of $1.92.
About Brainstorm Cell Therapeutics
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.
The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).
Recommended Stories
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
